Pankaj Mohan Bought 149% More Shares In Sonnet BioTherapeutics Holdings \

Even if it's not a huge purchase, we think it was good to see that Pankaj Mohan, the Founder of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) recently shelled out US$83k to buy stock, at US$0.22 per share. Even though that isn't a massive buy, it did increase their holding by 149%, which is arguably a good sign.

View our latest analysis for Sonnet BioTherapeutics Holdings

Sonnet BioTherapeutics Holdings Insider Transactions Over The Last Year

In fact, the recent purchase by Pankaj Mohan was the biggest purchase of Sonnet BioTherapeutics Holdings shares made by an insider individual in the last twelve months, according to our records. Even though the purchase was made at a significantly lower price than the recent price (US$0.29), we still think insider buying is a positive. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

Pankaj Mohan purchased 431.60k shares over the year. The average price per share was US$0.27. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Insider Ownership Of Sonnet BioTherapeutics Holdings

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. From our data, it seems that Sonnet BioTherapeutics Holdings insiders own 10% of the company, worth about US$599k. We do generally prefer see higher levels of insider ownership.

So What Does This Data Suggest About Sonnet BioTherapeutics Holdings Insiders?

It is good to see the recent insider purchase. And the longer term insider transactions also give us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Sonnet BioTherapeutics Holdings stock. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Case in point: We've spotted 7 warning signs for Sonnet BioTherapeutics Holdings you should be aware of, and 6 of these make us uncomfortable.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here